Key Takeaways
- Sequential recovery, EU-GMP the linchpin: Revenue rebounded 12% QoQ and EBITDA more than doubled, but the full margin and growth story hinges on the final EU-GMP certification, now described as "almost at the end."
- Innovation-led portfolio scaling fast: NIP and OTF revenue grew 84% YoY to ₹14.9 crore, now contributing 14% of total operating income; management sees EU registration as the trigger to cross a ₹20-25 crore per quarter barrier.
- Cost base reset underway: H1 margins were compressed by a ~₹5.5 crore one-time remediation and consultation expense layer plus new-facility ramp costs; management expects these not to fully recur, positioning for operating leverage in H2.
- Australia opens a new developed-market door: TGA GMP certification received, first test order in hand, commercial supplies expected Q3 FY27 and meaningful revenue from Q4.
- What to watch next quarter: Whether the EU-GMP certificate arrives within the 1-1.5 month window management anticipates, and whether the UK immediately converts its informal supply commitment into first commercial orders.
EU-GMP Remediation: The Central Catalyst
- Re-inspection completed, final report pending: A joint German-Portuguese regulatory team re-inspected the Nagpur facility in May 2026; a draft final report has been received and the signed final report is expected shortly.
- CAPA response proactively submitted: Based on draft observations, a CAPA response was filed and shared with inspectors; authorities have since requested clarifications, which management characterizes as documentation-only with no further physical work required.
- 90% acceptance milestone achieved: A letter from authorities indicates acceptance of the CAPA and action taken on major points up to 90%, a milestone management says also serves as the trigger point for UK approval to start supplies.
- Clarification response imminent: The remaining clarifications are in preparation and will be submitted within a few days; management believes the process is effectively at its conclusion.
- Certificate timeline depends on EMA cadence: Once clarifications are accepted, the EMA meets every 1-1.5 to 2 months; management expects the GMP certificate 1 to 1.5 months after acceptance, though the exact timing rests with authorities.
- No further CAPEX required: All remediation-related capital investment is complete; current capacity and investments are sufficient to reach approximately ₹700 crore in revenue without additional EU-GMP-specific spending.
Dr. Anwar Daud: "We have received reactions which do not warrant any further work. They require further clarification and a little more documentation, which are in the process of preparation. And within a few days, we will be responding with our set of documents on the clarifications that are being asked for. So, I believe we are almost at the end of this process."
Revenue Trajectory & Market Access
- FY27 target set with and without EU: Management targets ₹415-420 crore without any EU contribution; if EU orders come in, an additional ₹30-40 crore could push the full-year figure to ₹450-460 crore.
- H2 growth built on new market openings: Even without EU, 15-20% growth over H1 is expected for the legacy business, driven by registrations converting in LATAM, MENA, Africa, and Southeast Asia, plus the contribution of a reorganized international business development team.
- UK positioned as first EU market: An informal commitment from UK authorities indicates supplies can start once CAPA acceptance is confirmed; the UK is expected to deliver the majority chunk of Pancreatin business for at least the next year.
- Australia commercial ramp beginning: TGA GMP certification received; commercial supplies expected to begin in Q3 FY27, with meaningful revenue from Q4 FY27 and into FY28 once repeat orders come.
- EU product pipeline ready to activate: 8-10 products are lined up for launch once EU-GMP is obtained, including 5-6 nearing end of procedure, 5-6 in NIP, and 2-3 in OTF; contracts are signed for almost all products and client follow-up is continuous.
- Pancreatin and Tamsulosin as EU anchors: Pancreatin is projected to contribute ₹70-80 crore and Tamsulosin ₹20-30 crore of EU revenue next year, with the remaining products individually at ₹5-10 crore.
- ROW filings support sustained base growth: 48 formulation filings were made this quarter in ROW markets; management expects 5-10 new product launches per month over the next 12-18 months as filings convert to registrations.
Zain Daud: "The clients are continuously behind us to supply. All we are waiting for is EU-GMP. ... the demand seems to be there. The orders are there. It is just the regulatory clearance we are waiting for."
Margin Structure & Cost Reset
- QoQ margin improvement driven by topline: EBITDA margin improved 365 bps sequentially to 7.3% in Q2 FY27 from 3.7% in Q1, as higher revenue absorbed fixed costs more effectively.
- H1 margin compression explained: H1 FY27 EBITDA margin was 5.6% versus 8.4% in H1 FY26; the monthly operating expense run rate rose to approximately ₹15.5 crore from ₹13 crore, driven by new hiring for Nutra and CEPHA projects under validation, plus approximately ₹5.5 crore in one-time remediation and consultation expenses.
- One-time cost layer receding: EU-GMP consultant fees and certain separation costs incurred in H1 are not expected to fully recur in H2 or next year; management is executing cost rationalization including shifting operations from older Unit-3 and ancillary units to the new, more automated Nutraceutical facility.
- Operating leverage threshold identified: Management states EBITDA margin will normalize once revenue crosses ₹430-440 crore; above ₹450 crore, margin will increase sequentially with revenue, with normalized levels expected next year.
- Long-term margin framework maintained at 18-20%: At approximately ₹700 crore revenue, management expects 18-20% EBITDA margin as most operating costs will be covered and operating leverage fully kicks in; management acknowledges the framework could yield higher margins but prefers to wait for a constant EU supply stream before revising guidance upward.
Zain Daud: "A lot of it has also been capitalized because it has been infrastructure and systems we have put in for the EU-GMP remediation. There are a lot of consultant costs and one-time expenses which we have to do in terms of OPEX, which you are right, will not repeat going forward in H2 also and next year. So, we are looking to be a bit leaner on that part."
Innovation-Led Portfolio: NIP & OTF
- Rapid YoY scaling: NIP and OTF revenue grew 84% YoY to ₹14.9 crore in Q2 FY27, contributing 14% of total operating income (16% including dossier licensing fees); H1 FY27 contribution including license income reached ₹33.7 crore, a 68% increase over H1 FY26.
- EU registration as the step-change trigger: Three NIP products are at the end-of-procedure stage in the EU, awaiting EU-GMP certification for completion of the market authorization grant process; once obtained, management expects the segment to cross a ₹20-25 crore per quarter barrier.
- Marketing authorizations progressing: Four marketing authorizations were received during Q2 FY27, one for an NIP product and three for OTF products, building the commercial base ahead of developed-market access.
Balance Sheet & Investment Footprint
- Debt reflects completed investment cycle: Total debt stood at approximately ₹146.2 crore as of 30th September 2026; term loan increased to ₹84.1 crore from ₹60.7 crore at FY26-end, funding a gross block increase to ₹418.8 crore from ₹386.2 crore.
- Capacity adequate through 2030: Management believes no substantial CAPEX is needed to fulfill all orders expected through 2030; only operational CAPEX for machinery upgrades is anticipated, and current capacity has significant room to grow.
- Utilization at scale: At ₹700 crore revenue, capacity utilization is projected at 80-90%, depending on product mix; expansion CAPEX may be needed 1-2 years down the line if growth continues.
- R&D investment sustained: H1 FY27 R&D and related initiatives investment was approximately ₹18.2 crore; Q2 FY27 allocation was ₹9.9 crore or 9.4% of total operating income, including ₹4.5 crore toward bio-equivalent studies and regulatory filings.
Zain Daud: "We feel that we don't need to do substantial CAPEX to complete all of the orders that will come in till 2030. I think we may need to do some operational CAPEX, which comes with the business as pharma is to upgrade some of the machinery if it comes, but nothing substantial is needed."
Segment & Geographic Mix
| Segment / Market | Trend | Commentary |
|---|---|---|
| Pharmaceutical (core) | ▲ Steady | Contributed ~₹83 crore or 79% of total operating income in Q2; H1 FY27 pharma revenue grew 16% YoY. |
| Nutraceutical | ▲ Strong growth | Grew 58% YoY in H1 FY27; facility modernized with new automated setup now operational. |
| NIP & OTF | ▲ Scaling | 84% YoY growth in Q2; 14% of total income; EU registration seen as the major acceleration trigger. |
| Exports | ▲ Broad-based | Contributed ~86% of total operating income in Q2; LATAM, Southeast Asia, Middle East, and Africa all contributed almost equally to export growth. |
| Australia | ▲ New entry | TGA certification received; first test order in hand; commercial supplies Q3, meaningful revenue from Q4. |
| Saudi Arabia | ▬ Pre-revenue | No revenue impact in H1 as Saudi commercials have not yet started for Zim. |
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EU-GMP clarification response | Submit documentation responding to authority clarifications | Within a few days from the call |
| EU-GMP certificate receipt | Certificate expected 1-1.5 months after CAPA acceptance, subject to EMA meeting cadence | 1-1.5 months post-acceptance |
| UK commercial supplies | Supplies to begin once CAPA acceptance confirmed by authorities | Upon CAPA acceptance |
| Australia commercial supplies | Commercial supplies to begin | Q3 FY27 |
| FY27 revenue without EU | ₹415-420 crore | FY27 full year |
| FY27 revenue with EU orders in Q4 | ₹450-460 crore | FY27 full year |
| H2 FY27 growth over H1 | 10% base growth; 15-20% growth on H1 number | H2 FY27 |
| EBITDA margin normalization | Return to previous margin levels once revenue crosses ₹430-440 crore; normalized EBITDA margin expected next year | Next year |
| Long-term EBITDA margin | 18-20% at ~₹700 crore revenue | When ₹700 crore revenue achieved |
| Capacity sufficiency | No substantial CAPEX needed to fulfill orders | Through 2030 |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Total operating income | ₹105.4 cr, +19% YoY and +12% QoQ |
| EBITDA | ₹7.7 cr, broadly flat YoY vs ₹7.8 cr in Q2 FY26; margin 7.3% vs 3.7% in Q1 FY27 |
| EBITDA margin | 7.3%, improved 365 bps QoQ; lower YoY owing to cost base set-up for new businesses |
| Net loss | ₹2.1 cr, narrowed from ₹4 cr in Q1 FY27 |
| Pharmaceutical revenue | ₹83 cr, 79% of total operating income |
| NIP and OTF revenue | ₹14.9 cr, +84% YoY; 14% of total operating income, or 16% including dossier license fees |
| Export contribution | 86% of total operating income |
| R&D allocation | ₹9.9 cr, 9.4% of total operating income, including ₹4.5 cr for bio-equivalent studies and regulatory filings |
| Total debt | ₹146.2 cr, comprising term loan of ₹84.1 cr and working capital loan of ₹62.1 cr |
| Gross block | ₹418.8 cr, up from ₹386.2 cr at end of FY26 |
| Marketing authorizations received | 4, 1 NIP product and 3 OTF products |
| Filings across Pharmerging and ROW markets | 48 |
| NIP products at end of procedure stage in EU | 3 |
| One-time expenses (EU-GMP remediation, consultation fees) | ₹5.5 cr in H1 FY27, expected to reduce going forward |